Thursday, July 13, 2023
Fortis Life Sciences successfully acquires International Point of Care (IPOC). The Toronto-based IPOC specializes in the development and manufacturing of crucial diagnostic components, including lyophilized reagents, membranes, recombinant proteins, and controls. This acquisition empowers Fortis to offer a comprehensive end-to-end solution to enhance the immunodiagnostic and molecular diagnostic products for its customers. IPOC's expanded 36,000 sq. ft. facility, compliant with GMP and ISO 13485 standards, becomes Fortis' third manufacturing site in North America, strengthening its diagnostic capabilities.
Fred Pettijohn, Chief Business Officer of Fortis, stated, "Diagnostics and life sciences companies are seeking a partner that can provide tailored design and validation of reagents, ensure quality control and cost-effectiveness through in-house manufacturing, and accelerate time-to-market for their products. IPOC is a perfect complement to our existing capabilities, and we are excited to introduce our expanded solution to the market."
David Ray, CEO of IPOC, expressed enthusiasm about joining Fortis and offering customers a comprehensive range of high-quality materials and services. He emphasized that the combined expertise of both companies fully supports advancements in the diagnostic industry, including ultra-high-sensitivity, point-of-care, and multiplexing applications. Ray also highlighted their ability to contribute to emerging technologies such as quantitative lateral flow, isothermal amplification, and CRISPR-based diagnostics.